Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367006 | 0.89 | PTPN1 (0.34) | MEN1KMT2ABUB1F13A1TGM2 | |
| SCHEMBL22968909 | 0.89 | PTPN1 (0.34) | MEN1KMT2ABUB1F13A1TGM2 | |
| SCHEMBL21367005 | 0.89 | PTPN1 (0.34) | MEN1KMT2ABUB1F13A1TGM2 | |
| SCHEMBL5201608 | 0.88 | MEN1 (0.33) | MEN1KMT2AHSD17B10BUB1F13A1 | |
| SCHEMBL5201612 | 0.88 | MEN1 (0.33) | MEN1KMT2AHSD17B10BUB1F13A1 | |
| SCHEMBL22968912 | 0.84 | PTPN1 (0.30) | — | |
| SCHEMBL21358038 | 0.83 | ESR1 (0.32) | MEN1KMT2AESR1 | |
| SCHEMBL26098992 | 0.83 | ESR1 (0.32) | MEN1KMT2AESR1 | |
| SCHEMBL875307 | 0.80 | HSD17B10 (0.37) | MEN1KMT2AHSD17B10BUB1SMN1; SMN2 | |
| SCHEMBL875308 | 0.80 | HSD17B10 (0.37) | MEN1KMT2AHSD17B10BUB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2019177873-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | MEN1 2856/4885KMT2A 2770/4885HSD17B10 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.